bovnews5h
Trevi Therapeutics Inc (TRVI) Stock Rated Outperform by Leerink Partners
Notable insider trades include GOOD JENNIFER L, President & CEO at Trevi Therapeutics Inc (TRVI), who sold 40277 shares on Sep 05 ’24, at $3.11 each, totaling $0.13 million. On May 29 ’24, SCIASCIA ...
Leerink Partnrs Issues Positive Estimate for Opthea Earnings
Analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Opthea in a report released on Tuesday, October ...
Fintel on MSN7d
Leerink Partners Initiates Coverage of Voyager Therapeutics (VYGR) with Outperform Recommendation
Fintel reports that on October 16, 2024, Leerink Partners initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a ...
Leerink Partners' Affiliate, MEDACorp, Launches the Center for Pharmacoeconomics to Evaluate the Societal Impact of Healthcare Treatments
Leerink Partners' affiliate, MEDACorp, announced today the launch of a new division, the Center for Pharmacoeconomics (CPE), which will be dedicated to advancing the understanding of the societal ...
Leerink Partnrs Has Negative Outlook of Biohaven Q3 Earnings
Research analysts at Leerink Partnrs cut their Q3 2024 earnings per share (EPS) estimates for Biohaven in a report released ...
Seeking Alpha29d
Regeneron downgraded at Leerink after Amgen’s court win; Truist defends
Leerink Partners downgraded while Truist defended Regeneron (NASDAQ:REGN) after a judge denied the company’s motion for a preliminary injunction against Amgen (NASDAQ:AMGN) biosimilar for its ...
Mind Medicine assumed with an Outperform at Leerink
Leerink assumed coverage of Mind Medicine with an Outperform rating and $20 price target The firm likes the emerging ...
GEN2d
StockWatch: Wave’s RNA Editing Milestone Lifts Korro, ProQR
Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...
Investing5d
Leerink sees Tenaya's trial update as positive, maintains price target
On Friday, Leerink Partners maintained its positive stance on Tenaya Therapeutics Inc (NASDAQ:TNYA) with an Outperform rating and a steady price target of $8.00. This affirmation follows Tenaya's ...